Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002438 · ClinicalTrials.gov registry record · NA

A Study of Itraconazole in the Prevention of Histoplasmosis, a Fungal Infection, in HIV-Infected Patients

A NA study of HIV Infections and Histoplasmosis, sponsored by Janssen.

Completed
Registry status
NA
Development phase
7
Study locations

NCT00002438: Completed NA study of HIV Infections and Histoplasmosis, sponsored by Janssen.

NCT00002438 is a NA study of HIV Infections and Histoplasmosis that has completed, run by Janssen. The trial reports 7 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002438, a NA study of HIV Infections and Histoplasmosis, has completed, sponsored by Janssen.

COMPLETED
Registry status
NA
Development phase
7
Study locations

Study Summary

To assess the safety and efficacy of itraconazole versus placebo for prevention of histoplasmosis in HIV-infected patients with CD4 counts \< 150 cells/mm3 who reside where histoplasmosis is endemic. To assess the safety and efficacy of itraconazole for preventing other debilitating fungal infections, such as cryptococcosis, aspergillosis, recalcitrant oropharyngeal or vaginal candidiasis, and recurrent esophageal candidiasis.

Interventions

  • DRUG Itraconazole

Study Locations (7)

Tennessee

  • ASCC - Memphis
  • Dr Michael Threikeld - Memphis
  • Dr Mark A Pierce - Nashville

Indiana

  • Infectious Diseases Research Clinic / Indiana Univ Hosp - Indianapolis
  • Infectious Diseases of Indianapolis - Indianapolis

Missouri

  • Univ of Missouri at Kansas City School of Medicine - Kansas City
  • Infectious Diseases Association / Research Med Ctr - Kansas City

Trial Details

FieldValue
Phase NA
Janssen

10 total trials

What the finished NCT00002438 record still lists

NCT00002438 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Itraconazole is the first listed.

NCT00002438 lists 7 locations in 3 states (Tennessee, Indiana, Missouri).

Frequently Asked Questions

What is clinical trial NCT00002438 about?

NCT00002438 is a clinical study titled "A Study of Itraconazole in the Prevention of Histoplasmosis, a Fungal Infection, in HIV-Infected Patients". To assess the safety and efficacy of itraconazole versus placebo for prevention of histoplasmosis in HIV-infected patients with CD4 counts \< 150 cells/mm3 who reside where histoplasmosis is endemic. To assess the safety and efficacy of itraconazole for preventing other debilitating fungal infection...

What is the current status of trial NCT00002438?

This trial is currently completed. It is a NA study.

What conditions does trial NCT00002438 study?

This clinical trial studies the following conditions: HIV Infections, Histoplasmosis.

What interventions are being tested in trial NCT00002438?

The interventions under investigation include: Itraconazole (DRUG).

Who is sponsoring clinical trial NCT00002438?

This trial is sponsored by Janssen, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002438 being conducted?

This trial has 7 study locations across Indiana, Missouri, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Source: ClinicalTrials.gov NCT00002438, the US trial registry maintained by the National Library of Medicine. NCT00002438 (unsized enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.